Mar 05, 2020 8:00am EST SCYNEXIS Announces Preclinical Data on Ibrexafungerp and Azoles against Aspergillus Presented at the 9th Advances Against Aspergillosis and Mucormycosis Conference
Feb 13, 2020 8:08am EST SCYNEXIS Completes Patient Enrollment Ahead of Schedule in the Second Pivotal Phase 3 Study (VANISH-306) of Oral Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis (Vaginal Yeast Infection)
Jan 08, 2020 7:30am EST SCYNEXIS Announces Positive Results from the Second Interim Analysis of Ongoing Phase 3 FURI Study, Demonstrating Oral Ibrexafungerp's Ability to Treat Severe Fungal Infections in the Hospital Setting
Dec 16, 2019 8:30am EST SCYNEXIS Appoints Business Development Veteran Philippe Tinmouth to its Board of Directors
Dec 12, 2019 12:46pm EST SCYNEXIS Announces Closing of $35 Million Public Offering of Common Stock and Warrants
Dec 10, 2019 6:22am EST SCYNEXIS Announces Pricing of $35 Million Public Offering of Common Stock and Warrants
Nov 14, 2019 8:30am EST SCYNEXIS Commends the CDC for the Recognition of Candida auris as a New "Urgent Threat" in its Updated Report on Antibiotic Resistance Threats in the United States
Nov 12, 2019 8:30am EST SCYNEXIS Reports Third Quarter 2019 Financial Results and Provides Company Update
Nov 07, 2019 8:00am EST SCYNEXIS Reports Positive Top-Line Results from First Phase 3 Registration Study of Oral Ibrexafungerp in Vulvovaginal Candidiasis (VANISH-303)
